Bispecific Diabodies for Cancer Therapy
Natural killer (NK) cells represent a potent subset of lymphocytes for targeting and lysing tumor cells. In contrast to T lymphocytes, they do not need to be preactivated in vitro because they constitutively express cytolytic functions against a number of different targets (1 ,2 ). Their inherent cytolytic activity can be stimulated via the FcγIIIA receptor (CD16), which is expressed on the surface of NK cells, macrophages, and activated monocytes (3 ,4 ). Bispecific antibodies binding to both CD16 and a tumorassociated antigen are therefore of great interest as potential reagents for cancer immunotherapy.
- 上一篇
An Overview: From Discovery of Candidate Mutations to Disease Modeling and Transformation Mechanisms
Acute leukemia is an aggressive form of hematological malign...
- 下一篇
Colloidal Gold: A Novel Nanoparticle for Targeted Cancer Therapeutics
Since their initial description in 1857, gold nanoparticles ...